嵌合抗原受体T细胞治疗实体瘤。

Q1 Medicine

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2022-12-15 DOI:10.56875/2589-0646.1028

Jingmei Hsu, Yang Yang, Mia Gergis, Xia Bi, Dongni Yi, Usama Gergis

{"title":"嵌合抗原受体T细胞治疗实体瘤。","authors":"Jingmei Hsu, Yang Yang, Mia Gergis, Xia Bi, Dongni Yi, Usama Gergis","doi":"10.56875/2589-0646.1028","DOIUrl":null,"url":null,"abstract":"Chimeric antigen receptor T (CAR T) cell therapy has revolutionized the management of lymphoid malignancies. However, it is still in its early phase and is facing many obstacles in solid tumors. Therapeutic challenges in solid tumor lead to tumor target diversification and drive new innovations for the improvement of clinical efficacy. This review showcases early clinical works and sheds light on the most notable successes, drawbacks, and strategies employed to allow CAR T therapy to go full speed ahead.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"15 3","pages":"94-99"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chimeric Antigen Receptor T Cell Therapy For Solid Tumors.\",\"authors\":\"Jingmei Hsu, Yang Yang, Mia Gergis, Xia Bi, Dongni Yi, Usama Gergis\",\"doi\":\"10.56875/2589-0646.1028\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chimeric antigen receptor T (CAR T) cell therapy has revolutionized the management of lymphoid malignancies. However, it is still in its early phase and is facing many obstacles in solid tumors. Therapeutic challenges in solid tumor lead to tumor target diversification and drive new innovations for the improvement of clinical efficacy. This review showcases early clinical works and sheds light on the most notable successes, drawbacks, and strategies employed to allow CAR T therapy to go full speed ahead.\",\"PeriodicalId\":39226,\"journal\":{\"name\":\"Hematology/ Oncology and Stem Cell Therapy\",\"volume\":\"15 3\",\"pages\":\"94-99\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology/ Oncology and Stem Cell Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.56875/2589-0646.1028\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology/ Oncology and Stem Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.56875/2589-0646.1028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

嵌合抗原受体T (CAR - T)细胞治疗已经彻底改变了淋巴细胞恶性肿瘤的管理。然而，它仍处于早期阶段，在实体瘤中面临许多障碍。实体瘤的治疗挑战导致肿瘤靶点的多样化，为提高临床疗效提供了新的创新。这篇综述展示了早期的临床工作，并阐明了最显著的成功、缺点和策略，以使CAR - T疗法全速前进。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Chimeric Antigen Receptor T Cell Therapy For Solid Tumors.

Chimeric antigen receptor T (CAR T) cell therapy has revolutionized the management of lymphoid malignancies. However, it is still in its early phase and is facing many obstacles in solid tumors. Therapeutic challenges in solid tumor lead to tumor target diversification and drive new innovations for the improvement of clinical efficacy. This review showcases early clinical works and sheds light on the most notable successes, drawbacks, and strategies employed to allow CAR T therapy to go full speed ahead.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hematology/ Oncology and Stem Cell Therapy Medicine-Hematology

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

27 weeks

期刊介绍： Hematology Oncology and Stem Cell Therapy is an international, peer-reviewed, open access journal that provides a vehicle for publications of high-quality clinical as well as basic science research reports in hematology and oncology. The contents of the journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors.The journal prioritizes publication of original research articles but also would give consideration for brief reports, review articles, special communications, and unique case reports. It also offers a special section for clinically relevant images that provide an important educational value.